A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans.
We conducted a systematic search to describe the current state of knowledge regarding the utility of saliva for clinical pharmacokinetic monitoring (CPM) of antibiotics. Although the majority of identified studies lacked sufficient pharmacokinetic data needed to assign an appropriate suitability classification, most aminoglycosides, fluoroquinolones, macrolides, penicillins/cephalosporins, and tetracyclines are likely not suitable for CPM in saliva. No clear pattern of correlation was observed between physiochemical properties that favor drug distribution into saliva and the likelihood of the antibiotic being classified as suitable for CPM in saliva (and vice versa). Insufficient data were available to determine if pathophysiological conditions affected salivary distribution of antibiotics. Additional confirmatory data are required for drugs (especially in patients) that are deemed likely suitable for CPM in saliva because only a few studies were available and many focused only on healthy subjects. All studies identified had relatively small sample sizes and exhibited large variability. Very few studies reported salivary collection parameters (e.g., salivary flow, pH) that could potentially have some impact on drug distribution into saliva. The available data are heavily weighted on healthy subjects, and insufficient data were available to determine if pathophysiology had effects on saliva drug distribution. Some studies also lacked assay sensitivity for detecting antibiotics in saliva. Overall, this review can be useful to clinicians who desire an overview on the suitability of saliva for conducting CPM of specific antibiotics, or for researchers who wish to fill the identified knowledge gaps to move the science of salivary CPM further.
Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.
Tony K L
TK
Kiang
Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada. ensom@mail.ubc.ca.|Pharmacy Department (0B7), Children's and Women's Health Centre of British Columbia, 4500 Oak Street, Vancouver, BC, V6H 3N1, Canada. ensom@mail.ubc.ca.
Mary H H
MH
Ensom
D000617:Aminoglycosides / Q000493:pharmacokinetics; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D016903:Drug Monitoring; D024841:Fluoroquinolones / Q000493:pharmacokinetics; D006801:Humans; D018942:Macrolides / Q000493:pharmacokinetics; D010406:Penicillins / Q000493:pharmacokinetics; D012463:Saliva / Q000378:metabolism*; D013754:Tetracyclines / Q000493:pharmacokinetics
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D018942:Macrolides; D010406:Penicillins; D013754:Tetracyclines